key: cord-0742519-6vyaroz0
authors: Ciccarese, G.; Drago, F.; Parodi, A.
title: Comment on “Pityriasis rosea in a COVID-19 Pediatric Patient”
date: 2021-10-04
journal: Actas Dermosifiliogr
DOI: 10.1016/j.adengl.2021.09.016
sha: d21e3f05bfa56898ab478ad9dd9da8e3d7e3d25a
doc_id: 742519
cord_uid: 6vyaroz0

nan

more common 5 and after the introduction of the COVID-19 vaccinations also the diagnosis of PR-like eruptions has increased 6 .

The patient described by Öncü INS et al. 1 received a diagnosis of PR but, regrettably, several peculiar features of the disease have not been reported. The authors did not mention the possible presence of the herald patch and of oropharyngeal lesions 7 , the latter common in children 2 , nor systemic/local symptoms that can justify the treatment with betamethasone valerate ointment, 10% urea and cetirizine. Indeed, to date, no treatment is recommended on the basis of evidence-based medicine since PR is a self-limiting exanthemous disease that needs just reassurance and rest 6 Histopathology of the lesional skin biopsy, (that should be numbered in the article as Figure 2 ) 1 really shows extravasated red blood cells in the dermis, that is quite typical of PR, but that the authors incorrectly described as " perivascular erythocyte infiltration" 1 .

Lastly, the defined "COVID-19 infection" should be changed more properly with "SARS-CoV-2 infection".

Pityriasis Rosea in a Confirmed COVID-19 Pediatric Patient

Pityriasis Rosea: A Comprehensive Classification

Pityriasis rosea and pityriasis rosealike eruption: can they be distinguished?

Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease

Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases

Oropharyngeal lesions in pityriasis rosea

The efficacy of macrolides and acyclovir in pityriasis rosea

Pityriasis Rosea during Pregnancy: Major and Minor Alarming Signs

SARS-CoV-2 as possible inducer of viral reactivations